Overall survival poor in unresected anaplastic thyroid CA
The researchers found that the median OS was 2.27 months, and 11 percent of patients were alive at one year. There was a positive correlation for RT dose and survival for the entire study cohort, for those receiving systemic therapy, and for those with stage IVA, B, and C disease. Older age, one or more comorbidities, and distant metastases correlated with OS in multivariate analyses (hazard ratios, 1.317, 1.587, and 1.385, respectively); there were also correlations for receipt of systemic therapy (hazard ratio, 0.637) and for receipt of RT versus no RT (<45 Gy: hazard ratio, 0.843; 45 to 59.9 Gy: hazard ratio, 0.596; and 60 to 75 Gy: hazard ratio, 0.419). Propensity-score matching confirmed the RT dose-survival correlation for patients who received higher (60 to 75 Gy) versus lower (45 to 59.9 Gy) therapeutic doses.

Read more at: https://medicalxpress.com/news/2017-01-survival-poor-unresected-anaplastic-thyroid.html#jCp